옵션 체인은 다양한 행사가격과 만기일에 대한 Crinetics Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Crinetics Pharmaceuticals에 대한 시장 심리를 평가합니다..

Crinetics Pharmaceuticals (NASDAQ:CRNX) 주식, 옵션 체인

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals Inc

JP Morgan analyst Mark Murphy downgrades Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) from Neutral to Underweight and raises the price target from $21 to $22.5.

Downgrades

Price Target

Analyst Ratings

PYCR

JP Morgan Downgrades Paycor HCM to Underweight, Raises Price Target to $22.5

JP Morgan analyst James Kirby initiates coverage on Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) with a Overweight rating and announces Price Target of $23.

Initiation

SNCY

JP Morgan Initiates Coverage On Sun Country Airlines with Overweight Rating, Announces Price Target of $23

JP Morgan analyst DS Kim downgrades New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Overweight to Neutral and lowers the price target from $85 to $50.

New Oriental Education & Technology Group

JP Morgan Downgrades New Oriental Education to Neutral, Lowers Price Target to $50

Tesla Inc. CEO Elon Musk cast doubt Wednesday on the ambitious $500 billion Project Stargate, hours after its announcement, claiming lead investor SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) has &#8220;well under $10B secured.&#8221;
What Happened: The project, unveiled Tuesday at a White House briefing in the presence of President Donald Trump, represents a joint venture between OpenAI, SoftBank, and Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to establish massive <a href="https://www.benzinga.com/25/01/43111153/nvidia-and-ai-stock-rises-as-trump-announces-500-billion-stargate-ai-infrastructure-venture">artificial intelligence infrastructure across the United States</a>. 
&#8220;They don't actually have the money,&#8221; Musk said.
&#8220;SoftBank has well under $10B secured. I have that on good authority.&#8221;
During the briefing, Oracle co-founder Larry Ellison highlighted the project&#8217;s healthcare applications, including an AI-driven system capable of delivering personalized cancer vaccines within 48 hours. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">SoftBank has well under $10B secured. I have that on good authority.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1881944244480565497?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/biotech/25/01/43119814/google-parent-owned-startup-to-launch-ai-designed-drug-trials-by-year-end-partnering-with-eli-lilly-and-novartis-to-tackle-major-diseases">Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases</a>
Why It Matters: The initiative plans to deploy an initial $100 billion immediately, starting with a 500,000-square-foot data center in Abilene, Texas. Nine additional facilities are planned, with potential expansion to 20 locations.
Technology partners Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) saw their stocks climb on the news. NVIDIA rose 3.95% to $143.15, while Arm jumped 8.94% to $162.60.
OpenAI, maintaining operational responsibility while SoftBank leads financial aspects, stated the project &#8220;will secure American leadership in AI&#8221; and &#8220;create hundreds of thousands of American jobs.&#8221; SoftBank&#8217;s Masayoshi Son will serve as chairman.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies">Netflix Raises Prices 16%, Peter Schiff Warns Of Escalating Inflation Risks Ahead Of Trump Policies</a></li>
</ul>
Image via Wikimedia Commons
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

MSFT

NVDA

ORCL

SFTBF

SFTBY

Elon Musk Says Project Stargate Doesn't 'Actually Have The Money' After Trump Announces $500 Billion AI Investment Led By SoftBank, Oracle And OpenAI

Jefferies analyst Dennis Ding upgrades Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) from Hold to Buy and announces $55 price target.

Upgrades

Jefferies Upgrades Crinetics Pharmaceuticals to Buy, Announces $55 Price Target

Canaccord Genuity analyst Caitlin Burrows initiates coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy rating and announces Price Target of $24.

OFIX

Canaccord Genuity Initiates Coverage On Orthofix Medical with Buy Rating, Announces Price Target of $24

Canaccord Genuity analyst Maria Ripps upgrades Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Hold to Buy and raises the price target from $940 to $1150.

NFLX

Canaccord Genuity Upgrades Netflix to Buy, Raises Price Target to $1150

HUIZ

Huize Stated That It Served Over 1.3 Million Families With More Than 12 Million Insurance Policies Facilitated And Assisted In Processing 160,800 Insurance Claims (+74.7% YoY) In 2024

Shares of Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) rose sharply in today's pre-market trading as the company reported stronger-than-expected <a href="https://www.benzinga.com/news/earnings/25/01/43114866/netflix-q4-earnings-record-subscribers-nfl-squid-game-push-past-highest-expectations">fourth-quarter financial results</a>.
Netflix reported it added 18.91 million paid subscribers in the fiscal quarter, up 15.9% year-over-year. The company said it sees full-year revenue of $43.5 billion to $44.5 billion, up $0.5 billion from the company's previous range
Netflix shares jumped 14.6% to $996.60 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ImmunoPrecise Antibodies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) gained 58.8% to $0.7833 in pre-market trading. ImmunoPrecise Antibodies recently launched its AI-powered pipeline of both optimized and new therapeutics.</li>
<li>New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) rose 42% to $3.89 in pre-market trading. New Era Helium recently announced a joint venture with Sharon AI to construct and develop a 250MW net-zero energy data center..</li>
<li>Cardio Diagnostics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) rose 40.2% to $0.8520 in pre-market trading after jumping around 15% on Tuesday.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) gained 25.7% to $1.13 in pre-market trading after jumping 94% on Tuesday.</li>
<li>U.S. Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) gained 21.5% to $4.61 in pre-market trading after surging 63% on Tuesday.</li>
<li>Metagenomi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) gained 20.2% to $3.27 in pre-market trading following a 4% gain on Tuesday.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 14.7% to $54.65 in pre-market trading. Tempus AI shares jumped over 35% on Tuesday after Nancy Pelosi disclosed the purchase of 50 Jan 2026 call options.</li>
<li>CareCloud, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) gained 13.3% to $3.50 in pre-market trading after surging over 10% on Tuesday.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) gained 13.2% to $29.63 in pre-market trading after gaining around 7% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Associated Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) fell 43.7% to $20.00 in pre-market trading. Associated Capital recently reported estimated fourth quarter and full year results</li>
<li>Star Fashion Culture Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STFS#NASDAQ">STFS</a>) shares fell 20.7% to $10.72 in pre-market trading after dipping around 9% on Tuesday.</li>
<li>HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) fell 19.5% to $0.68 in pre-market trading after the company announced the receipt of a Staff Delisting Notice.</li>
<li>Lisata Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) shares dipped 17.4% to $3.22 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Septerna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) fell 14.4% to $16.01 in pre-market trading after gaining more than 10% on Tuesday.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares tumbled 13.1% to $0.8949 in pre-market trading after the company announced exercise of warrants and issuance of new warrants in a private placement for $3.7 million gross proceeds priced at-the-market.</li>
<li>Dogwood Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares fell 13% to $2.74 in pre-market trading. Dogwood Therapeutics shares jumped 68% on Tuesday after the company announced patient dosing for its Phase 2b trial evaluating halneuron will commence in Q1 2025.</li>
<li>AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) declined 12.3% to $14.81 in pre-market trading after gaining over 6% on Tuesday.</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) fell 11.8% to $4.45 in today's pre-market trading. InMed Pharmaceuticals recently announced that INM-901 reduced Alzheimer &#8216;s-related inflammation in a preclinical study.</li>
<li>Marine Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPX#NYSE">MPX</a>) dipped 11.3% to $8.04 in pre-market trading. Marine Products will release its financial results for the fourth quarter on Thursday, Jan. 30, before the market opens.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

ANAB

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DWTX

HSDT

HUBC

LSTA

NEHC

SEPN

STFS

USEG

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Accolade Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>), Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), Cameco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>), and Absci Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>).
The trades include defense and energy companies, which have been in focus since the inauguration of Donald Trump. The President signed orders on Monday aimed at making it cheaper for companies to produce oil and gas, which could have an impact on energy companies. Defense stocks have also been in focus due to expectations of a pro-Israel stance from the new administration.
The NTLA Trade
The Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) collectively purchased 91,889 shares of Intellia Therapeutics Inc. Based on the closing price of $9.94, the total value of the trade amounts to approximately $913,580.06. This move indicates Ark&#8217;s continued confidence in the gene-editing sector.
The PATH Trade
Ark Invest sold 21,879 shares of UiPath Inc. through its ARKK fund. Given the closing price of $13.33, the trade is valued at around $291,712.07. This sale suggests a shift in Ark&#8217;s stance on the automation software company.
The DE Trade
Ark Invest&#8217;s ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) purchased a total of 3,474 shares of Deere &amp; Co. With the closing price at $463.15, the trade is worth approximately $1,607,571.10.
The CCJ Trade
Ark Invest also bought 17,504 shares of Cameco Corp (CCJ) through its ARKQ fund, valued at approximately $937,589.44 at the closing price of $53.56.
Other Key Trades:
<ul>
<li>Oklo Inc: Ark Invest sold 50333 shares through ARKQ.</li>
<li>Elbit Systems: Ark Invest Sold 2074 shares through ARKQ and 627 shares through ARKX.</li>
<li>Illumina Inc: Ark Invest bought 15876 shares through ARKG.</li>
<li>Absci Corp: Ark Invest bought 79411 shares through ARKG.</li>
<li>Accolade Inc: Ark Invest sold 466,337 shares through ARKG.</li>
</ul>
Photo courtesy: Ark Invest

ABSI

ACCD

ARKG

ARKK

ARKQ

ARKX

ESLT

ILMN

NTLA

OKLO

PATH

Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies

Shares of Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) experienced a 15% surge in premarket trading on Wednesday on the heels of the company announcing a 16%<a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies" target="_blank" rel="noreferrer noopener"> price hike for its standard streaming plan.</a>
What Happened: Netflix&#8217;s shares saw an increase of $128.14 in the premarket, following a 1.35% rise at the close of the previous day, ending at $869.68. 
The price increase, which took the&nbsp;ad-free standard plan from $15.49&nbsp;to $17.99 per month, was announced in conjunction with Netflix&#8217;s impressive fourth-quarter earnings report.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment" target="_blank" rel="noreferrer noopener">Oracle's Larry Ellison Says Cancer Vaccine Tailored In 48 Hours Could Soon Be A Reality As Trump Announces $500 Billion AI Investment</a>
The earnings report highlighted a 16% year-over-year revenue growth, reaching $10.25 billion, and a subscriber increase of 18.91 million. This surge in subscribers brought the total number of paid memberships to a staggering 301.63 million. The price increase also impacted the premium tier, now priced at $24.99, and the ad-supported option, which rose to $7.99.
Netflix&#8217;s robust performance, marked by a <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">record operating income surpassing</a>&nbsp;$10 billion for fiscal 2024,&nbsp;suggests a promising future for the company. Netflix anticipates its 2025 revenue to fall&nbsp;between $43.5 billion and $44.5&nbsp;billion, indicating a 12-14% growth. This projection underscores Netflix&#8217;s relatively&nbsp;small current share of the&nbsp;estimated $650 billion market opportunity&nbsp;across its key regions.
The company&#8217;s strong performance, driven by popular shows like &#8216;Squid Game&#8217; and its NFL content, has led to a significant <a href="https://www.benzinga.com/25/01/43104552/youtube-vs-netflix-streamers-top-usage-leaderboard-in-december-sector-makes-more-gains-on-broadcast-and-cable">increase in its subscriber base.</a> The price hike, which is the largest in the company&#8217;s history, is a bold move that reflects Netflix&#8217;s confidence in its future growth and content offerings.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43118598/warren-buffetts-pilot-co-exits-global-oil-trading-refocuses-on-us-operations-report" target="_blank" rel="noreferrer noopener">Warren Buffett's Pilot Co Exits Global Oil Trading, Refocuses On US Operations: Report</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Netflix Rises 15% In Wednesday Premarket As Streaming Giant Hikes Prices Following Record Subscriber Growth

LOGI

Logitech Announced Rally Board 65, An All-in-one Portable Video Conference Solution That Combines Intelligent Audio And Video With A 65" Touchscreen Display

Logitech Introduced Logitech Spot, A Workplace Occupancy And Environmental Sensor That's Simple To Deploy In Nearly Any Space

UTSI

UTStarcom Announced That It Has Been Selected As A Major Winner Of The RFP "Self-developed STN-A Equipment Hardware Production And OEM Procurement Project" From Guangdong Research Institute Of China Telecom Co., Ltd

Marqeta Announced It Is Powering Trading 212's Launch Into 20 Countries In Continental Europe

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is now looking to hire data labelers in Utah for <a href="https://www.benzinga.com/news/24/07/39705124/tesla-giving-special-treatment-to-musk-and-high-profile-vip-drivers-in-fsd-development-report">data from its fleet of vehicles</a> as well as its Tesla bots.
What Happened: Tesla posted job openings on social media platform X and its career page.
The employees will work with in-house tools to label data coming from the company&#8217;s large fleet of vehicles as well as data from its humanoid bots which are under development. The data will include images and videos and the labeling will contribute to advancing the software aimed at making them operate autonomously. 
&#8220;No&nbsp;previous&nbsp;experience in AI or data labeling&nbsp;required. The perfect candidate for this role is adaptable, can apply logic to multiple different scenarios, is attentive to detail, has experience with computers and other software, and enjoys a fast-paced work environment,&#8221;&nbsp;the company says in the job description. The candidate must also have a working knowledge of the laws and rules of the road, it added. 
The job will be full-time and would require the employee to work from 9 am to 5:30 pm for five days a week in Utah.
Why It Matters: Tesla uses the visual road data that it gains from its car fleet to train their software how to respond autonomously to them. The company is hopeful that its autopilot and full self-driving (FSD) software, which currently serve as driver assistance systems, will enable autonomous driving with time and more training. 
Last year, Tesla CEO Elon Musk said that the company would start deploying self-driving Model 3 and Model Y vehicles in Texas and California for ride-hailing in 2025, provided it gets the necessary regulatory clearances.
However, the vehicles might not all operate as driverless robotaxis but with a driver as some states demand it until the company touches certain milestones in terms of miles and hours driven, the company then said. Musk, known for overestimating his company's products, expressed confidence about the&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41279865/elon-musk-may-unveil-teslas-robotaxi-but-consumers-respond-with-ehhh-new-study-reveals-skepticism-ne" target="_blank" rel="noreferrer noopener">company operating driverless paid rides sometime in 2025</a>.
However, it is important to note that FSD has yet to enable autonomous driving and still requires active driver supervision. 
As for Tesla bots, Musk said in July that the EV company would have "genuinely useful" humanoid robots in low production for use within its factories in 2025. The company will "hopefully" increase production for other customers in 2026, he said.
Musk expects to be&nbsp;<a href="https://www.benzinga.com/news/24/03/37950895/elon-musk-says-cost-of-making-an-optimus-is-half-that-of-manufacturing-a-tesla-ev-despite-complexity" target="_blank" rel="noreferrer noopener">able to sell Optimus, as the bots are called, at $10,000 or $20,000</a>, at a lower price point than Tesla&#8217;s cheapest Model 3 sedan, once it reaches high-volume production.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
<li></li>
</ul>
Image via Tesla

Tech

TSLA

Tesla Looks To Hire Data Labelers To Boost Autonomous Vehicle And Bot Development

Billionaire Peter Thiel, a renowned venture capitalist and co-founder of PayPal Holdings and Palantir Technologies, got into Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investments long before its meteoric bull runs captured the world's attention.
However, the long-held conviction appeared to fade, as apparent from one of his interviews last year.
What happened: During an interview in Jun. 2023, Thiel <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39569413/billionaire-peter-thiel-voices-skepticism-on-bitcoins-future-growth-im-not-sure-its-going-">voiced pessimism about Bitcoin's price rise potential</a>.&nbsp;
"I'm not sure it's going to go up that dramatically from here. We got the ETF edition, and I don't know who else buys it," the venture capitalist said.
Thiel added that the apex cryptocurrency has grown increasingly connected with traditional finance as a result of the launch of spot exchange-traded funds, a deviation from its original cypherpunk, crypto-anarchist narrative.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43119637/michael-saylors-proposal-to-increase-microstratagys-share-count-approved-by-shareholders-more-bitcoin-purchases-on-the-cards">Michael Saylor&#8217;s Proposal To Increase MicroStratagy&#8217;s Share Count Approved By Shareholders — More Bitcoin Purchases On The Cards?</a>
When Thiel made these remarks, Bitcoin traded at $60,320.14 per unit. So, if you set aside his skepticism and invested $1,000 in the asset, you'd have received 0.0165 BTC.
Fast forward to January, and the apex cryptocurrency has made significant strides, exchanging hands at $104,988.38 as of this writing.&nbsp;
So if you'd have resisted selling, the original investment would have turned $1740.52, netting a return of 74% in just about seven months.
Why It Matters: Thiel's venture capital firm, Founders Fund, has had a&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37087400/peter-thiels-founders-fund-bets-big-on-bitcoin-and-ether-with-200m-investment-report#google_vignette" target="_blank" rel="noreferrer noopener">significant history with Bitcoin</a>, first buying the apex digital asset back in 2014.
The fund made a profit of $1.8 billion on its Bitcoin investments by selling just before the 2022 market collapse.
It returned to the market between late summer and early fall of 2023, purchasing $100 million worth of Bitcoin.
Interestingly, in the very same interview where Thiel expressed doubts about Bitcoin, he regretted not purchasing more of the digital currency.
Price Action: At the time of writing, Bitcoin was exchanging hands at $104,988.38, up 2.73% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Year-to-date, the leading cryptocurrency has gained 12.41%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43118234/president-trump-signs-executive-order-to-pardon-silk-road-creator-ross-ulbricht">President Trump Signs Executive Order To Pardon Silk Road Creator Ross Ulbricht</a></li>
</ul>
Photo By Mark Reinstein On Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

If You Invested $1,000 In Bitcoin When Billionaire Peter Thiel Said BTC  Might Not Rise 'Dramatically,' Here's How Much You'd Have Made Today

<h3>Companies Reporting Before The Bell</h3>
• HDFC Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $422.93 billion. 
• Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) is likely to report quarterly earnings at $6.61 per share on revenue of $10.80 billion. 
• Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) is projected to report quarterly earnings at $1.86 per share on revenue of $21.59 billion. 
• Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) is projected to report quarterly earnings at $1.26 per share on revenue of $837.57 million. 
• GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) is expected to report quarterly earnings at $2.37 per share on revenue of $10.70 billion. 
• Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is likely to report quarterly earnings at $2.02 per share on revenue of $22.45 billion. 
• Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) is likely to report quarterly earnings at $1.28 per share on revenue of $3.27 billion. 
• Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) is projected to report quarterly earnings at $5.23 per share on revenue of $1.45 billion. 
• TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) is projected to report quarterly earnings at $1.89 per share on revenue of $3.91 billion. 
• OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $176.15 million. 
• F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $408.00 million. 
• LG Display Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPL#NYSE">LPL</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $5.87 billion. 
• HBT Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBT#NASDAQ">HBT</a>) is likely to report quarterly earnings at $0.58 per share on revenue of $57.48 million. 
• Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) is estimated to report quarterly earnings at $0.70 per share on revenue of $5.63 billion. 
• BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $261.25 million. 
• United Community Banks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCB#NYSE">UCB</a>) is likely to report earnings for its fourth quarter. 
• Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) is projected to report quarterly earnings at $1.34 per share on revenue of $11.04 billion. 
• Commerce Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBSH#NASDAQ">CBSH</a>) is projected to report quarterly earnings at $0.89 per share on revenue of $417.18 million. 
• Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) is expected to report quarterly earnings at $0.64 per share on revenue of $2.01 billion. 
• Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $4.06 billion. 
<h3>Companies Reporting After The Bell</h3>
• Triumph Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) is likely to report quarterly earnings at $0.25 per share on revenue of $108.44 million. 
• Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) is projected to report quarterly earnings at $1.63 per share on revenue of $3.98 billion. 
• Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) is likely to report quarterly earnings at $0.52 per share on revenue of $87.75 million. 
• Old Second Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSBC#NASDAQ">OSBC</a>) is likely to report quarterly earnings at $0.48 per share on revenue of $59.62 million. 
• Wesbanco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBC#NASDAQ">WSBC</a>) is estimated to report quarterly earnings at $0.55 per share on revenue of $156.42 million. 
• First Internet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBK#NASDAQ">INBK</a>) is expected to report quarterly earnings at $0.91 per share on revenue of $24.88 million. 
• NVE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEC#NASDAQ">NVEC</a>) is estimated to report earnings for its third quarter. 
• Univest Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UVSP#NASDAQ">UVSP</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $73.45 million. 
• SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) is likely to report quarterly earnings at $1.53 per share on revenue of $156.30 million. 
• Cohen &amp; Steers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNS#NYSE">CNS</a>) is projected to report quarterly earnings at $0.81 per share on revenue of $140.72 million. 
• Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $4.13 billion. 
• Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $1.88 billion. 
• Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) is estimated to report quarterly earnings at $0.91 per share on revenue of $55.96 million. 
• RLI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) is expected to report quarterly earnings at $1.04 per share on revenue of $435.02 million. 
• CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) is expected to report quarterly earnings at $5.23 per share on revenue of $2.02 billion. 
• Eagle Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGBN#NASDAQ">EGBN</a>) is estimated to report quarterly earnings at $0.49 per share on revenue of $74.67 million. 
• Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $480.50 million. 
• National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) is likely to report quarterly earnings at $0.79 per share on revenue of $107.38 million. 
• QCR Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) is projected to report quarterly earnings at $1.73 per share on revenue of $96.56 million. 
• Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is projected to report quarterly earnings at $1.09 per share on revenue of $185.11 million. 
• Bankwell Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWFG#NASDAQ">BWFG</a>) is projected to report quarterly earnings at $0.65 per share on revenue of $22.12 million. 
• Third Coast Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBX#NASDAQ">TCBX</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $41.96 million. 
• Plexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) is projected to report quarterly earnings at $1.55 per share on revenue of $980.53 million. 
• Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) is expected to report quarterly earnings at $0.54 per share on revenue of $131.10 million. 
• Amerant Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTB#NYSE">AMTB</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $100.68 million. 
• Horizon Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNC#NASDAQ">HBNC</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $62.78 million. 
• Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $457.77 million. 
• Colony Bankcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBAN#NYSE">CBAN</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $28.90 million. 
• Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) is estimated to report quarterly earnings at $1.21 per share on revenue of $156.09 million. 
• Alcoa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $3.29 billion. 
• Discover Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) is estimated to report quarterly earnings at $3.26 per share on revenue of $4.39 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ALLY

AMTB

BANR

BWFG

CACI

CADE

CATY

CBAN

CBSH

EGBN

EQBK

HBNC

INBK

NBHC

NVEC

OSBC

PLXS

QCRH

STLD

TCBX

TFIN

UVSP

WSBC

Earnings Scheduled For January 22, 2025

The CNN Money Fear and Greed index showed further improvement in overall market sentiment, but the index remained in the &#8220;Fear&#8221; zone on Tuesday.
U.S. stocks settled higher on Tuesday, with the Dow Jones index gaining more than 500 points during the session as investors bet on more domestic-friendly policies following Donald Trump&#8217;s inauguration on Jan. 20 as the 47th U.S. President.
All three major indices also recorded their first weekly gain of 2025. The Dow jumped 3.7%, while the S&amp;P 500 added 2.9% last week. The Nasdaq, meanwhile, surged 2.5% during the week to notch its strongest weekly performance since December.
D.R. Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) reported better-than-expected first-quarter results. 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) reported upbeat fourth-quarter 2024 results and initiated 2025 guidance.
Most sectors on the S&amp;P 500 closed on a positive note, with industrials, real estate, and health care stocks recording gains on Tuesday. However, energy stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 538 points to 44,025.81 on Tuesday. The S&amp;P 500 rose 0.88% to 6,049.24, while the Nasdaq Composite climbed 0.64% at 19,756.78 during Tuesday's session.
Investors are awaiting earnings results from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 40.8, the index remained in the &#8220;Fear&#8221; zone on Tuesday, versus a prior reading of 37.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock"> Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone

Hal Sperlich, the automotive genius behind the <a href="https://www.benzinga.com/news/24/04/38285214/fords-mustang-gallops-into-60th-year-still-a-pony-with-plenty-of-kick">Ford Mustang</a>, passed away on Monday at 95. 
What Happened: Sperlich is best known as the chief architect behind the Ford Mustang and the Chrysler minivan. A Detroit and Saginaw native, Sperlich trained to be an engineer at the University of Michigan. He joined Ford in 1957 as a product planner and went on to develop the Mustang.
After leaving Ford, Sperlich joined Chrysler in 1977 and directed the company&#8217;s engineering personnel to develop a front-wheel-drive platform that became the &#8220;K-Car&#8221; which later gave rise to the company&#8217;s minivans. He was inducted into the Automotive Hall of Fame in 2009.
The news of his passing was first<a href="https://www.autonews.com/executives/an-obituary-hal-sperlich/"> reported</a> by Automotive News.
Ford CEO Responds: Ford CEO Jim Farley expressed his condolences on Tuesday in a post on social media platform X. 
&#8220;We lost a product visionary in Hal Sperlich. He was also a friend and mentor to me, and many others.&nbsp; Hal was a dare-to-be-different product planner who had vision, passion and knowledge of a customers' wants and needs,&#8221; Farley said. The CEO noted that Sperlich was behind the Ford Fiesta in addition to <a href="https://www.benzinga.com/25/01/42938610/ford-sold-more-electric-mustangs-than-gas-mustangs-in-2024">the Mustang.</a>
&#8220;He didn't play it safe, and he was always focused on the whitespace&nbsp;and improving the company's capability.&nbsp;There are a lot of people who make great cars but so few who invent segments like Hal did with the Ford Mustang and later the Fiesta,&#8221; Farley said. &#8220;Our hearts go out to his family and friends.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We lost a product visionary in Hal Sperlich. He was also a friend and mentor to me, and many others.  Hal was a dare-to-be-different product planner who had vision, passion and knowledge of a customers' wants and needs. He didn't play it safe, and he was always focused on the… <a href="https://t.co/Gmh4Q1RU3f">https://t.co/Gmh4Q1RU3f</a>
&mdash; Jim Farley (@jimfarley98) <a href="https://twitter.com/jimfarley98/status/1881820033632137417?ref_src=twsrc%5Etfw">January 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43090016/which-evs-might-lose-7500-ev-tax-credit-under-trump-administration" target="_blank" rel="noreferrer noopener">Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration</a></li>
</ul>
Photo courtesy: Ford

Ford Mustang Architect Hal Sperlich Dies At 95: 'Lot Of People Who Make Great Cars But So Few Who Invent Segments Like Hal Did,' Says Jim Farley

Leerink says Crinetics (CRNX) this morning reported positive Phase 2 topline biomarker and clinical results for atumelnant in congenital adrenal hy...

Crinetics data 'compelling' despite safety concerns, says Leerink

Crinetics falls after mid-stage trial data adrenal disorder therapy

In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report)...

Crinetics Pharmaceuticals Receives Buy Rating on Promising Phase 2 Trial Results and Strong Financial Position

Analyst David Lebowitz from Citi maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) and keeping the price target at $74....

Crinetics Pharmaceuticals: Promising Phase 2 Results and Strong Growth Potential Lead to Buy Rating

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) yesterday and set a price target ...

Strong Buy Recommendation for Crinetics Pharmaceuticals Driven by Promising Atumelnant Phase 2 Trial Results

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on CRNX stock, giving a Buy rating yesterday. Jessica Fye's rating is based on ...

Crinetics Pharmaceuticals: Promising Trial Data and Strategic Advancements Support Buy Rating

H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on CRNX stock, giving a Buy rating on January 10. Douglas Tsao's rating is...

Promising Phase 2 Results for Atumelnant Boost Crinetics Pharmaceuticals' Buy Rating

An update from Crinetics Pharmaceuticals ( ($CRNX) ) is now available. At the J.P. Morgan Healthcare Conference in January 2025, Crinetics Pharmace...

Crinetics Pharmaceuticals Outlines 2025 Strategic Priorities

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report), with a...

Piper Sandler Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in the ...

Crinetics upgraded to Buy from Hold at Jefferies

Press Releases

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Health Care

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Comments

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals (CRNX) 옵션

Crinetics Pharmaceuticals (NASDAQ:CRNX) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌